Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
These findings provide preclinical validation for the use of anti-GIPR antibodies in the treatment of obesity
These drugs have shown to be very effective in producing weight loss in patients
Study design To test the hypothesis, we designed a 16-week, single-blinded, randomized, placebo-controlled clinical trial, to compare the effects of semaglutide versus placebo in women, diagnosed with obesity and polycystic ovarian syndrome (PCOS)
Tirzepatide is a dual agonist targeting both GLP-1 and GIP receptors, improving insulin sensitivity and promoting fullness, leading to superior weight losssome patients lose over 20%, with an average of 15%
Other GLP-1 drugs like Wegovy and Zepbound were developed and tested specifically for obesity treatment with higher doses optimized for weight management outcomes
Clean, smart, and effective - so you can shine brighter every day
US$ 22.03
US$ 29.29
US$ 21.28
